In the EXHALE-4 study, dexpramipexole met the primary endpoint with statistically significant improvement in lung function ...

Dexpramipexole was well tolerated, and had a favorable safety profile.

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

AstraZeneca’s RESOLUTE phase III trial of Fasenra to treat chronic obstructive pulmonary disease fails to meet primary endpoint: Cambridge, UK Thursday, September 18, 2025, 15:0 ...

Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

In the EXHALE-4 study, dexpramipexole met the primary endpoint with statistically significant improvement in lung function compared with placebo Dexpramipexole demonstrated statistically significant ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Three years on from a splashy unveiling, Areteia Therapeutics has reported a phase 3 victory that could boost its bid to launch an oral rival to the biologics that dominate a multibillion-dollar ...

Privately-held Areteia Therapeutics has announced positive results from the Phase III EXHALE-4 efficacy and safety study of ...

On 03 September 2025, Hoffmann-La Roche conducted a study is to assess the long-term safety and to explore the efficacy of ...

AstraZeneca said on Monday that asthma drug Fasenra had failed to meet core targets in trials involving patients with severe ...

A molecular allergy chip reliably detected allergic asthma, revealing that 73% of the study's asthma cohort had sensitization ...